Kansas Bioscience Authority Commits $4.3 Million to Support Professors
A prominent pharmaceutical scientist with 20 years of industrial research and development experience joined the KU faculty earlier this month, thanks in part to a five-year, $2.5 million financial commitment from the Kansas Bioscience Authority.
David Volkin comes to KU from Centocor R&D, a subsidiary of Johnson & Johnson, as the Takeru and Aya Higuchi Distinguished Professor in the Department of Pharmaceutical Chemistry. He will establish his lab in the Simons Biosciences Research Laboratories, focusing on vaccine and biopharmaceutical drug development. He also joins KUs Laboratory for Macromolecular and Vaccine Stabilization, located in the Multidisciplinary Research Building.
KU is known nationally for our outstanding School of Pharmacy and its research achievements, said Chancellor Bernadette Gray-Little. The cancer center initiative and strategic hires such as this one are building research and commercialization capacity in vital areas of human health that benefit all Kansans.
Volkin will have one more title as well. In November, the Kansas Bioscience Authority Board voted to name him an Eminent Scholar. That designation carries with it significant startup and ongoing support from the organization.
David Volkin adds another dimension to KUs incredibly strong drug delivery and development programs, said Tom Thornton, Kansas Bioscience Authority president and CEO. His industry background complements those strengths and promises to bolster a KBA priority: translating university bioscience research into economic development for Kansas.
Volkin was introduced Jan. 26 at a ceremony at the Capitol in conjunction with the annual Kansas Bioscience Day. Speaking at that ceremony were Gray-Little, Thornton and Kansas Bioscience Authority Chair John Carlin.
Also at the ceremony, it was announced that the Kansas Bioscience Authority Board of Directors has designated Rakesh Srivastava of the KU Cancer Center as an Eminent Scholar. He will be supported by a five-year, $1.8 million Kansas Bioscience Authority commitment. Srivastava came to the KU Medical Center last fall from the University of Texas Health Science Center at Tyler. He is a professor of pharmacology, toxicology and therapeutics.
Volkin and Srivastava are KUs second and third Eminent Scholars. Blake Peterson, the Regents Distinguished Professor of Medicinal Chemistry, was first in 2008.
Volkin held senior director positions for Centocor in pharmaceutical research and development from 2002 through 2009. Before that, he held similar management as well as research scientist positions with Merck Research Laboratories from 1989 to 2002. He also worked for two years as a research technician at the Research Institute of Scripps Clinic.
Volkins academic background includes a bachelors in chemistry from the University of California-San Diego and a doctorate in biochemical engineering from the Massachusetts Institute of Technology.
KU is an exciting opportunity, Volkin said. It has outstanding faculty in the School of Pharmacy and a clear vision for research and the education of future pharmacists. The west campus expansion is a tremendous investment, with two new research buildings in place and two other buildings the School of Pharmacy classroom building and the Bioscience and Technology Business Center scheduled for completion in 2010. I look forward to coming to Lawrence, and I very much appreciate the commitment the KBA is making in our research program. Kansas Bioscience Authority commits $4.3 million to support professorsA prominent pharmaceutical scientist with 20 years of industrial research Conduct By Rakesh Srivastava